JS 003
Alternative Names: JS-003Latest Information Update: 06 Jan 2025
At a glance
- Originator Shanghai Junshi Biosciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 06 Jan 2025 Phase-I development is ongoing in China (Shanghai Junshi Biosciences pipeline, January 2025)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Solid-tumours in China
- 09 Apr 2022 JS 003 is still in phase I trials for Solid tumours in China (Shanghai Junshi Bioscience pipeline, April 2022)